Cornerstone Dermatology — Excellence in dermatology
Specialist skin care in Coorparoo(07) 3397 3200
HomeCornerstone Centre for Clinical Research

Cornerstone Centre for Clinical Research

Dr Kim and the nursing staff have a passion for clinical trials which is why our clinical trial unit was created. Our clinical Trial unit is operated under the direction of Dr Kim, Teagan Holland and Margaret Anders.

Various pharmaceutical companies conduct clinical trials for the development of new effective treatments for various skin conditions. Dr Kim completed his Master of Medicine from the University of Sydney through a clinical trial on vitamin D, and has been involved in a number of other clinical trials.

Cornerstone Dermatology has special interest in clinical trials. Please enquire about ongoing clinical trials the clinic is currently involved in.

Active, Recruiting, and upcoming Clinical Trials

Atopic Dermatitis (Eczema)

  1. A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis – Click here
  2. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis – Click Here
  3. A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study With an Open-label Period Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Participants with Moderate to Severe Atopic Dermatitis

Alopecia Areata

  1. A Pilot, Safety and Clinical Activity, Phase 1b Study of DR-01 in Adults With Alopecia Areata or Vitiligo – Click here
  2. A Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata – Click here

Plaque Psoriasis

  1. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis – Click Here

Weight Loss

  1. Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for the Treatment of Obesity and Weight-Related Comorbidities in Adolescents: A Randomized, Double-Blind, Placebo- Controlled Trial – Click here

Vitiligo

  1. A Pilot, Safety and Clinical Activity, Phase 1b Study of DR-01 in Adults With Alopecia Areata or Vitiligo – Click here
  2. A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-Segmental Vitiligo – Click Here

Chronic Spontaneous Urticaria (CSU)

  1. A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU2) – Click here

Non-melanoma Skin Cancers (NMSC)

  1. A Phase 1, Open Label, First in Human (FIH) Study Investigating Photodynamic Therapy (PDT) with INV043 0.5% Ointment in Adults with Non-melanoma Skin Cancers

Systemic Lupus (SLE), Cutaneous Lupus (CLE), Sjogren’s Syndrome, Primary Sjögren Syndrome, Dermatomyositis, Polymyositis, Scleroderma, Diffuse Sclerosis, Diffuse Cutaneous Systemic Sclerosis (dcSSc)

  1. A Phase 1, Open-label, Multiple Ascending Dose Basket Study to Evaluate the Safety and Activity of DR-0201 in Patients With Select Autoimmune Rheumatic Diseases – Click Here

Hypertrophic Sternotomy Scar

  1. An Integrated Phase 1a/1b, First-in-human, Randomized, Double-blinded, Placebo-controlled Split-scar Study in a Cohort of Adult Participants with Hypertrophic Sternotomy Scars to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics – Click Here

Type 2 Diabetes

  1. A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and With Type 2 Diabetes – Click Here

Cosmetic

  1. Abdominal Subcutaneous Fat reduction in adults

For expressions of interest to participant in a clinical trial, please contact our Clinical Trials Team on: 

Phone: (07) 2102 5054

Fax:      (07) 3397 3900

Email:  [email protected]

Principal Investigator:

    • Dr Young Jin Kim

Sub Investigator:

  • Dr Shiva Baghaei

Clinical Nurse Specialist/Nurse Researcher:

  • Teagan Holland
  • Margaret Anders

Our Clinical Trial team has worked with the following medications which are now approved for use in Australia for the following conditions:

Atopic Dermatitis (Eczema)

  • Dupilumab (Dupixent)
  • Upadacitinib (Rinvoq)

Hidradenitis Suppurativa (HS)

  • Adalimumab (Humira)

Psoriasis

  • Ixekizumab (Taltz)
  • Apremilast (Otezla)
  • Adalimumab (Humira)
  • Secukinumab (Cosentyx)
  • Guselkumab (Tremfya)
  • Tildrakizumab (Ilumya)
  • Risankizumab (Skyrizi)
  • Deucravacitinib (Sotyktu)

Chronic Spontaneous Urticaria (CSU)

  • Omalizumab (Xolair)